Creo Medical Group PLC First use of Speedboat(R) UltraSlim in Latin America
10 Janeiro 2024 - 4:00AM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
10 January 2024
Creo Medical Group plc
("Creo" the "Company" or the "Group")
First use of Speedboat(R) UltraSlim in Latin America
12 patients treated in three days
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces that
its latest device, Speedboat(R) UltraSlim, has now been
successfully used in Latin America for the first time.
Speedboat(R) UltraSlim was used at the Ecuadorian Institute of
Digestive Diseases ("IECED") in late December, where Dr Carlos
Robles Medranda, Dr Michel Kahaleh and Dr Eduardo Albeniz,
supported by the Creo clinical team, performed 12 procedures using
Speedboat(R) UltraSlim over three days, as well as performing the
first ever F-POEM procedure with the device. F-POEM (Endoscopic
Fundoplication Peroral Endoscopic Myotomy) is a minimally invasive
endoscopic procedure used to treat oesophageal motility disorders
in patients who are prone to gastroesophageal reflux.
Following the limited market release of Speedboat(R) UltraSlim
in December 2023 the device has been successfully used in multiple
clinical applications and was used in the UK, USA to treat
precancerous lesions in the colon, oesophagus and stomach, in
addition to performing oesophageal and gastric POEM procedures (a
procedure which addresses swallowing disorders and
gastroparesis).
Carlos Robles-Medranda, Head of the Endoscopy Service at IECED,
said: "I had the privilege of hosting these distinguished
physicians, facilitating the successful execution of 12 procedures
over three days using Speedboat UltraSlim. The excitement around
the device was noticeable, and we eagerly anticipate the positive
impact it will have on enhancing our patient pathways as we look to
address an increased number of cases."
Dr Michel Kahaleh, who performed many of these procedures at
IECED, commented: "From the very first time when I saw the device,
I knew that it was born to do POEM procedures. It allowed me to
glide over the muscularis when tunnelling. Once you have acquired
the knowledge to use this technology, you're really going to save
procedure time. The technology allows the endoscopist to complete
an F-POEM procedure with a single device, whereas previously it
required three different devices."
Craig Gulliford, Chief Executive Officer of Creo Medical, said:
"The procedures done at IECED have shown the full potential of the
new Speedboat UltraSlim. We were thrilled to witness the successful
execution of the F-POEM procedure using solely the Speedboat
device, a task that traditionally requires three separate
instruments. This not only showcases the device's efficiency but
also enhances the cost-effectiveness of the procedure, underscoring
the economic advantages Creo's technology can deliver to our valued
customers."
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cavendish Capital Markets Limited +44 (0)20 7220 0500
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson (Sales)
Deutsche Numis (Joint Broker)
Freddie Barnfield / Duncan Monteith
/ Euan Brown +44 (0)20 7260 1000
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices,
bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation, and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
About Speedboat(R) UltraSlim
Speedboat(R) UltraSlim is the third device in Creo's
Speedboat(R) family of products, and is targeting the therapeutic
treatment of disease in the GI tract (including cancer of the
Bowel, Stomach and Oesophagus) as well as surgical procedures to
deal with abnormalities resulting in swallowing disorders and, in
some cases, gastric reflux. This latest generation Speedboat has
broad application in the GI tract due to a smaller configuration,
ensuring compatibility with a wide range of colonoscopes and
gastroscopes.
Powered by Creo's CROMA advanced energy platform, Speedboat(R)
UltraSlim delivers fluid as well as advanced bipolar RF energy for
controlled cutting and high frequency MW energy for controlled
coagulation of tissue in the GI tract. The device is the
culmination of a long programme of work to further miniaturise
Creo's technology, and is compatible with the working channel of
all commercially available endoscopes accessing the vast majority
of GI endoscopic procedures.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUAUGUPCPPB
(END) Dow Jones Newswires
January 10, 2024 02:00 ET (07:00 GMT)
Creo Medical (LSE:CREO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Creo Medical (LSE:CREO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024